Lumos Pharma’s (LUMO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Lumos Pharma (NASDAQ:LUMO) in a research note released on Thursday, Marketbeat reports. They currently have a $4.25 target price on the stock, down from their previous target price of $28.00.

A number of other brokerages also recently commented on LUMO. Oppenheimer reduced their price objective on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. EF Hutton Acquisition Co. I raised shares of Lumos Pharma to a “strong-buy” rating in a research note on Tuesday, September 24th.

Lumos Pharma Stock Performance

Shares of NASDAQ LUMO opened at $4.40 on Thursday. The firm has a market capitalization of $35.71 million, a price-to-earnings ratio of -0.96 and a beta of 0.78. The stock has a 50 day moving average price of $3.80 and a 200 day moving average price of $2.83. Lumos Pharma has a 52-week low of $1.37 and a 52-week high of $4.58.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.33. The firm had revenue of $0.49 million during the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same quarter in the previous year, the firm posted ($1.09) EPS. Analysts forecast that Lumos Pharma will post -2.96 earnings per share for the current year.

Hedge Funds Weigh In On Lumos Pharma

An institutional investor recently raised its position in Lumos Pharma stock. Private Advisor Group LLC raised its holdings in shares of Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 744,513 shares of the company’s stock after purchasing an additional 714,500 shares during the period. Private Advisor Group LLC owned 9.17% of Lumos Pharma worth $2,881,000 at the end of the most recent quarter. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.